



Fresenius Medical Care

## P R E S S   R E L E A S E

March 24, 2006  
Joachim Weith,  
Corporate Communications  
Tel.: +49-6172-6082101  
Fax: +49-6172-6082294  
e-mail: [pr@fmc-ag.com](mailto:pr@fmc-ag.com)  
[www.fmc-ag.com](http://www.fmc-ag.com)

### Fresenius Medical Care expands Production Capacity for Dialyzers in North America

**Bad Homburg, Germany** – Fresenius Medical Care AG & Co. KGaA (FWB: FME, FME3) (NYSE: FMS, FMS-p), the world's largest provider of dialysis products and services, today announced the expansion of its Ogden, Utah production facility. This expansion will increase the production capacity from 27 million to more than 33 million dialyzers annually. The plant expansion supports Fresenius Medical Care North America's commitment to provide single-use dialyzers to the U.S. market, which is estimated to be over 60% single-use dialyzer therapy, including independent dialysis care providers.

In North America, Fresenius Medical Care provides innovative treatment therapy through its UltraCare® program, which employs single-use dialyzers as the preferred method of care for approximately 90,000 patients in more than 1,150 clinics.

The expansion of the Ogden, Utah plant is expected to be completed during the first half of 2007. The capital expenditure for this expansion is included in the Company's 2006 financial guidance, and demonstrates a

clear commitment to meet the continued demand for the single-use dialyzer product line.

Rice Powell, CEO of the Products and Hospital Group and Co-CEO of FMCNA, commented. "It is clear from the growth in our single-use dialyzer product line that our customers prefer this modality to treat their patients who suffer from chronic kidney disease. We view this expansion as our pledge to the future of renal patient care. As the world's premier manufacturer of dialyzers, we believe this expansion will benefit the local community, our employees, our patients and our shareholders."

# # #

Fresenius Medical Care is the world's largest, integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,400,000 individuals worldwide. Through its network of approximately 1,680 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to approximately 131,450 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. For more information about Fresenius Medical Care visit the Company's website at [www.fmc-ag.com](http://www.fmc-ag.com).

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.